Adage Capital Partners
TRML

Adage Capital Partners’s Tourmaline Bio TRML Stock Holding History

Adage Capital Partners’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-135,637
Closed -$2.17M – 980
2025
Q2 		$2.17M Sell
135,637
-364,363
-73% -$5.9M ﹤0.01% 758
2025
Q1 		$7.61M Sell
500,000
-100,000
-17% -$1.6M 0.01% 637
2024
Q4 		$12.2M Buy
+600,000
New +$15.1M 0.02% 558

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Adage Capital Partners's TRML Position: Q3 2025 in Review

Adage Capital Partners sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 135,637 shares — an estimated $2.17M sold.

Adage Capital Partners first reported a position in TRML in Q4 2024 and held it in 3 quarters. The position peaked at $12.2M in Q4 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Adage Capital Partners reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 135,637 Tourmaline Bio shares in Q3 2025, an estimated $2.17M.
  • Adage Capital Partners first reported a position in Tourmaline Bio in Q4 2024 and held it in 3 quarters.
  • Adage Capital Partners's Tourmaline Bio position peaked at $12.2M in Q4 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.